Alyeska Investment Group L.P. Has $23 Million Stake in Paratek Pharmaceuticals Inc (PRTK)

Alyeska Investment Group L.P. grew its stake in shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) by 473.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 916,349 shares of the specialty pharmaceutical company’s stock after acquiring an additional 756,535 shares during the quarter. Alyeska Investment Group L.P. owned about 3.28% of Paratek Pharmaceuticals worth $23,000,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the company. Royce & Associates LP increased its holdings in shares of Paratek Pharmaceuticals by 3.6% during the third quarter. Royce & Associates LP now owns 293,200 shares of the specialty pharmaceutical company’s stock valued at $7,359,000 after acquiring an additional 10,300 shares in the last quarter. Allianz Asset Management GmbH increased its holdings in Paratek Pharmaceuticals by 6.0% in the 3rd quarter. Allianz Asset Management GmbH now owns 65,366 shares of the specialty pharmaceutical company’s stock worth $1,641,000 after buying an additional 3,719 shares in the last quarter. Omni Partners LLP bought a new stake in Paratek Pharmaceuticals in the 3rd quarter worth about $3,707,000. Moody Aldrich Partners LLC bought a new stake in Paratek Pharmaceuticals in the 3rd quarter worth about $1,081,000. Finally, Schwab Charles Investment Management Inc. increased its holdings in Paratek Pharmaceuticals by 124.4% in the 3rd quarter. Schwab Charles Investment Management Inc. now owns 82,164 shares of the specialty pharmaceutical company’s stock worth $2,063,000 after buying an additional 45,556 shares in the last quarter. Hedge funds and other institutional investors own 84.30% of the company’s stock.

Several equities research analysts recently commented on PRTK shares. BidaskClub downgraded Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, August 23rd. Cantor Fitzgerald reiterated a “buy” rating and issued a $50.00 price objective on shares of Paratek Pharmaceuticals in a report on Wednesday, August 23rd. Raymond James Financial reiterated a “strong-buy” rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. ValuEngine downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Finally, Zacks Investment Research downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $40.00.

Paratek Pharmaceuticals Inc (NASDAQ PRTK) opened at $17.45 on Monday. The company has a quick ratio of 10.53, a current ratio of 10.53 and a debt-to-equity ratio of 0.49. Paratek Pharmaceuticals Inc has a 12-month low of $13.15 and a 12-month high of $29.00.

ILLEGAL ACTIVITY WARNING: “Alyeska Investment Group L.P. Has $23 Million Stake in Paratek Pharmaceuticals Inc (PRTK)” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.com-unik.info/2017/12/11/alyeska-investment-group-l-p-has-23-million-stake-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals Inc (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

What are top analysts saying about Paratek Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Paratek Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit